<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-8909</journal-id>
<journal-title><![CDATA[Medicina crítica (Colegio Mexicano de Medicina Crítica)]]></journal-title>
<abbrev-journal-title><![CDATA[Med. crít. (Col. Mex. Med. Crít.)]]></abbrev-journal-title>
<issn>2448-8909</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Medicina Crítica A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-89092024000800644</article-id>
<article-id pub-id-type="doi">10.35366/120010</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Filtro adsorbente en la terapia de reemplazo renal continua. Una trampa perfecta en choque séptico: un estudio observacional retrospectivo unicéntrico del sureste mexicano]]></article-title>
<article-title xml:lang="en"><![CDATA[Adsorbent filter in the continous renal replacement therapy. The perfect trap in septic shock: an observational retrospective unicentric study from the Mexican southeast]]></article-title>
<article-title xml:lang="pt"><![CDATA[Filtro adsorvente na terapia de substituição renal continua. Uma armadilha perfeita no choque séptico: um estudo observacional retrospectivo unicêntrico do Sudeste mexicano]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López Fermin]]></surname>
<given-names><![CDATA[Jorge]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vásquez Añas]]></surname>
<given-names><![CDATA[Kipsia Elizabeth]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Zamora Guevara]]></surname>
<given-names><![CDATA[Iveth Soledad]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Zavaleta Hernández]]></surname>
<given-names><![CDATA[Blanca Flor]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado Hospital de Alta Especialidad ]]></institution>
<addr-line><![CDATA[Veracruz ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<volume>38</volume>
<numero>8</numero>
<fpage>644</fpage>
<lpage>649</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-89092024000800644&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-89092024000800644&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-89092024000800644&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[resumen está disponible en el texto completo]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  acute kidney injury in the setting of septic shock is associated with prolonged renal recovery and high mortality. Continuous renal replacement strategies are those techniques that include the continuous circulation of blood through extracorporeal circuits in order to purify it, and are part of the comprehensive treatment and care of patients with acute kidney injury. Therapy with an extracorporeal blood adsorbent filter establishes a causal model of endotoxin and cytokine elimination that could benefit patients with this entity.  Objective:  to compare the effectiveness of the adsorbent filter in the treatment of acute kidney injury in septic shock.  Material and methods:  we present a retrospective observational study carried out from September 2022 to January 2024 in the intensive care unit of a hospital center. All patients received CRRT for &#8805; 24 hours. The primary outcome was mortality. Secondary outcomes like days of renal replacement therapy and SOFA score were included.  Results:  a total of 52 patients with septic shock and acute kidney injury were added. The intervention group (oXiris group; n = 26) received CRRT with cytokine adsorption and endotoxic function hemofilter (oXiris), meanwhile, the control group (group ST150; n = 26) was treated with the hemofilter ST150. A goodness-of-fit test was performed establishing a non-parametric distribution group where a correlation coefficient Kendall rank was used. The variables of interest were oXiris group, ST 150 group, renal replacement therapy duration (TDTRR) and survival, showed bilateral significance; oXiris group and TDTRR R = 0.53 (p &#8804; 0.001), ST150 group and TDTRR R = &#8722;0.53 (p &#8804; 0.001) ST150 group and survival R = 0.46 (p &#8804; 0.001). A survival analysis was performed and a nominal level of significance was established using log rank. It was observed that early mortality in the oXiris group failed to increase life expectancy compared to the ST150 group, which increased 4.5 days the evaluation at 60 days in the oXiris group which didn&#8217;t demonstrate from the established nominal level of significance.  Conclusions:  the use of hemofilters with adsorbent property did not demonstrate an increase in life expectancy in our study population through a correlation analysis compared to a ST150 hemofilter. The cost-benefit evaluation is our argument due to the rational use of the adsorbent filter at our environment. Further researches in randomized controlled trials or high-quality prospective studies are needed to validate the present findings.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução:  a lesão renal aguda no contexto de choque séptico está associada a recuperação renal prolongada e elevada mortalidade. Estratégias de substituição renal contínua são aquelas técnicas que incluem a circulação contínua de sangue através de circuitos extracorpóreos para purificá-lo e fazem parte do tratamento e cuidado integral de pacientes com lesão renal aguda. A terapia com filtro extracorpóreo de adsorção de sangue estabelece um modelo causal de eliminação de endotoxinas e citocinas que poderia beneficiar pacientes com esta entidade.  Objetivo:  o objetivo do nosso trabalho foi comparar a eficácia do filtro adsorvente no tratamento da lesão renal aguda no choque séptico.  Material e métodos:  apresentamos um estudo observacional retrospectivo realizado de setembro de 2022 a janeiro de 2024 na unidade de terapia intensiva de um centro hospitalar. Todos os pacientes receberam CRRT por &#8805; 24 horas. Os resultados primários foram mortalidade. Os resultados secundários incluíram dias de terapia renal substitutiva e escore SOFA.  Resultados:  foram incluídos 52 pacientes com choque séptico e lesão renal aguda. O grupo intervenção (grupo oXiris; n = 26) recebeu CRRT com hemofiltro com adsorção de citocinas e função endotóxica (oXiris), enquanto o grupo controle (grupo ST150; n = 26) foi tratado com hemofiltro ST150. Foi efetuado um teste de bondade de ajuste estabelecendo uma distribuição não paramétrica por grupos, foi utilizado um coeficiente de correlação de rango Kendall, as variáveis de interesse grupo oXiris, grupo ST150, duração da terapia de substituição renal (TDTRR) e sobrevivência mostraram significância bilateral; grupo oXiris e TDTRR R = 0. 53 (p &#8804; 0.001), grupo oXiris e sobrevida R = &#8722;0.46 (p &#8804; 0.001), grupo ST150 e TDTRR R = &#8722;0.53 (p &#8804; 0.001), grupo ST150 e sobrevida R = 0.46 (p &#8804; 0.001). Foi realizada uma análise de sobrevivência e foi estabelecido um nível de significância nominal por meio do log rank. Observou-se que a mortalidade precoce no grupo oXiris não conseguiu aumentar a expectativa de vida em comparação ao grupo ST150, que aumentou 4.5 dias. A avaliação aos 60 dias no grupo oXiris não conseguiu demonstrar diferença em relação ao nível de significância nominal estabelecido.  Conclusão:  o uso de hemofiltros com propriedade adsorvente não conseguiu demonstrar um aumento na expectativa de vida em nossa população de estudo através de uma análise de correlação em comparação com um hemofiltro ST150. A avaliação custo-benefício é nosso argumento devido ao uso irracional do filtro adsorvente em nosso ambiente. Mais pesquisas em ensaios clínicos randomizados ou estudos prospectivos de alta qualidade são necessárias para validar os presentes achados.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[lesión renal aguda]]></kwd>
<kwd lng="es"><![CDATA[terapia de reemplazo renal continua]]></kwd>
<kwd lng="es"><![CDATA[adsorción]]></kwd>
<kwd lng="es"><![CDATA[oXiris]]></kwd>
<kwd lng="es"><![CDATA[choque séptico]]></kwd>
<kwd lng="en"><![CDATA[acute kidney injury]]></kwd>
<kwd lng="en"><![CDATA[continuous renal replacement therapy]]></kwd>
<kwd lng="en"><![CDATA[adsorption]]></kwd>
<kwd lng="en"><![CDATA[oXiris]]></kwd>
<kwd lng="en"><![CDATA[septic shock]]></kwd>
<kwd lng="pt"><![CDATA[lesão renal aguda]]></kwd>
<kwd lng="pt"><![CDATA[terapia de substituição renal contínua]]></kwd>
<kwd lng="pt"><![CDATA[adsorção]]></kwd>
<kwd lng="pt"><![CDATA[oXiris]]></kwd>
<kwd lng="pt"><![CDATA[choque séptico]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hoste]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Bagshaw]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Bellomo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cely]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Colman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[DN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study]]></article-title>
<source><![CDATA[Intensive Care Med]]></source>
<year>2015</year>
<volume>41</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1411-23</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bagshaw]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Uchino]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bellomo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Morimatsu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Morgera]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Schetz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes]]></article-title>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2007</year>
<volume>2</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>431-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gomez]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kellum]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sepsis-induced acute kidney injury]]></article-title>
<source><![CDATA[Curr Opin Crit Care]]></source>
<year>2016</year>
<volume>22</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>546-53</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kellum]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Mehta]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Angus]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Palevsky]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ronco]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The first international consensus conference on continuous renal replacement therapy]]></article-title>
<collab>ADQI Workgroup</collab>
<source><![CDATA[Kidney Int]]></source>
<year>2002</year>
<volume>62</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1855-63</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kramer]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Wigger]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Rieger]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Matthaei]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Scheler]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Arteriovenous haemofiltration: a new and simple method for treatment of over-hydrated patients resistant to diuretics]]></article-title>
<source><![CDATA[Klin Wochenschr]]></source>
<year>1977</year>
<volume>55</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>1121-2</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Uldall]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Continuous veno-venous hemofiltration (CVVH) in critically ill patients: a new approach to renal replacement therapy]]></article-title>
<source><![CDATA[Can J Surg]]></source>
<year>1987</year>
<volume>30</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>427-30</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ronco]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Reis]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Continuous renal replacement therapy and extended indications]]></article-title>
<source><![CDATA[Semin Dial]]></source>
<year>2021</year>
<volume>34</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>550-60</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<collab>Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group</collab>
<article-title xml:lang=""><![CDATA[KDIGO clinical practice guideline for acute kidney injury]]></article-title>
<source><![CDATA[Kidney Int Suppl]]></source>
<year>2012</year>
<volume>2</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-138</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rhodes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Alhazzani]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Antonelli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[(2016). Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016]]></article-title>
<source><![CDATA[Intensive Care Med]]></source>
<year>2016</year>
<volume>42</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1-43</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cutuli]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Artigas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fumagalli]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Monti]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ranieri]]></surname>
<given-names><![CDATA[VM]]></given-names>
</name>
<name>
<surname><![CDATA[Ronco]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Polymyxin-B hemoperfusion in septic patients: analysis of a multicenter registry]]></article-title>
<source><![CDATA[Ann Intensive Care]]></source>
<year>2016</year>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>77</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lobo]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ABDO-MIX: a randomized trial evaluating the effect of blood purification on endotoxemia in septic shock]]></article-title>
<source><![CDATA[J Crit Care]]></source>
<year>2014</year>
<volume>29</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>801-8</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ghosh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The EUPHRATES trial: a randomized controlled trial of polymyxin B hemoperfusion for endotoxemia in septic shock]]></article-title>
<source><![CDATA[J Am Med Association (JAMA)]]></source>
<year>2018</year>
<volume>320</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>292-301</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rhodes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Alhazzani]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Antonelli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Coopersmith]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[French]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surviving Sepsis Campaign: Guidelines for management of sepsis and septic shock: 2021]]></article-title>
<source><![CDATA[Crit Care Med]]></source>
<year>2021</year>
<volume>49</volume>
<numero>11</numero>
<issue>11</issue>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="">
<source><![CDATA[Clinicaltrials.gov]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shibata]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Miyamoto]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kato]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of the circulatory effects of continuous renal replacement therapy using AN69ST and polysulfone membranes in septic shock patients: a retrospective observational study]]></article-title>
<source><![CDATA[Ther Apher Dial]]></source>
<year>2020</year>
<volume>24</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>561-7</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multicenter study on critically ill patients with COVID-19]]></article-title>
<source><![CDATA[J Clin Med]]></source>
<year>2020</year>
<volume>9</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>2465</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="">
<collab>U.S. Food and Drug Administration (FDA)</collab>
<source><![CDATA[Emergency use authorization for oXiris hemofilter]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Deng]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of continuous renal replacement therapy with the oXiris hemofilter on critically ill patients: a narrative review]]></article-title>
<source><![CDATA[J Clin Med]]></source>
<year>2022</year>
<volume>11</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>6719</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A randomized controlled trial of oXiris-CRRT in patients with severe and critical COVID-19 without acute kidney injury]]></article-title>
<source><![CDATA[J Crit Care]]></source>
<year>2021</year>
<volume>61</volume>
<page-range>12-8</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
